|
CONNECT WITH US
|
|
||||||||||||||
We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling
pathways in the heterogeneous tumors of mesenchymal origin—spurred by the identification of c-Kit–activating
mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the
tyrosine kinase inhibitor imatinib (Gleevec).
In the current critical review we discuss these emerging trends in localized and systemic treatment as well as possible interesting combinations of the two modalities. Finally, we discuss the role of the new systemic agents in non–clear cell RCC.
This article will review the recent advances that form the current framework of therapy for RCC, as well as summarize key areas of progress and innovation in the evolving treatment paradigms for this disease.
Second Opinion series: The patient is a 43-year-old man who was initially evaluated at an outside institution for unexplained anemia and who was found to have a large right kidney mass.
This article reviews the existing data to formulate an overall management strategy of metastatic RCC patients and discusses ongoing investigative efforts including sequencing, combination therapy and novel agents.
A 48-year-old woman presents with history of hematuria and abdominal pain spanning several days. The patient does not have any previous tumor history. Radiological evaluation revealed the presence of a large mass in the upper pole of the right kidney. Right nephrectomy was performed.
A 3-year-old child was brought to the physician’s office after the mother felt a mass in the abdominal area. Imaging revealed the presence of a mass that appeared to be in the right kidney. Surgical resection of the tumor was performed.
A 28-year-old, slightly obese Caucasian woman presented with a long-standing history of intermittently painful “bumps” on both shoulders and her upper back. Review of systems disclosed regular but very heavy menstrual periods, often lasting for 7 to 9 days, and chronic constipation.
A 60-year-old woman developed metastatic renal cell carcinoma and was given oral sorafenib. Three weeks after commencing treatment, the patient became febrile without signs of localized infection and rapidly developed a nonpruritic, slightly tender cutaneous eruption.
CancerNetwork speaks with Dr. Michael Atkins, who has extensive clinical experience in kidney cancer and development of various new treatments, and is presenting this weekend during the renal cancer translational science session at the American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium.
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources
© 1996 - 2013 UBM Medica LLC, a
UBM company
Privacy Statement -
Terms of Service -
Advertising Information -
Editorial Policy Statement -
UBM Medica Network Privacy Policy